Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions (2019 - 2023)

Lineage Cell Therapeutics' Tax Provisions history spans 5 years, with the latest figure at -$1.8 million for Q1 2023.

  • For Q1 2023, Tax Provisions changed N/A year-over-year to -$1.8 million; the TTM value through Dec 2023 reached -$1.8 million, up 87.58%, while the annual FY2025 figure was -$5.3 million, N/A changed from the prior year.
  • Tax Provisions reached -$1.8 million in Q1 2023 per LCTX's latest filing, down from -$41000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $4.4 million in Q1 2019 to a low of -$14.0 million in Q4 2019.
  • Average Tax Provisions over 4 years is -$1.2 million, with a median of $250000.0 recorded in 2022.
  • The largest YoY upside for Tax Provisions was 153.46% in 2022 against a maximum downside of 153.46% in 2022.
  • A 4-year view of Tax Provisions shows it stood at -$14.0 million in 2019, then surged by 92.78% to -$1.0 million in 2021, then soared by 95.95% to -$41000.0 in 2022, then plummeted by 4297.56% to -$1.8 million in 2023.
  • Per Business Quant, the three most recent readings for LCTX's Tax Provisions are -$1.8 million (Q1 2023), -$41000.0 (Q4 2022), and $541000.0 (Q3 2022).